STOCK TITAN

Beryl and David Witkin Disclose 4.09M YMAB Shares (9.0%)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Beryl Capital Management and related reporting persons disclosed ownership of 4,087,091 shares of Y-mAbs Therapeutics common stock, representing 9.0% of the outstanding class based on 45,438,420 shares reported by the issuer for the quarter ended June 30, 2025. The Partnership affiliate is separately reported with 3,095,833 shares (6.8%). All reported shares are shown with shared voting and shared dispositive power; none are reported as sole voting or sole dispositive power. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Positive

  • Reported beneficial ownership of 4,087,091 shares (9.0% of class)
  • Certification states shares were acquired and are held in the ordinary course of business, not to influence control

Negative

  • No sole voting or dispositive power reported; all power is shared
  • Concentration in a single reporting group equals a material 9.0% stake, requiring disclosure and potential monitoring by investors

Insights

TL;DR: Beryl and affiliates report a material passive stake of 9.0% in Y-mAbs; holdings are shared, not sole-control.

The Schedule 13G discloses a material position: 4,087,091 shares equal to 9.0% of the class using the issuer's stated outstanding share count. The report classifies the position as passive under Rule 13d-1, and the filers state the securities are held in the ordinary course and not to influence control. For investors, this is a notable ownership disclosure but, per the filing, does not signal an active control campaign or immediate governance changes.

TL;DR: A single investor group and its control person hold shared voting rights on 9.0%—material but filed as non-control.

The filing identifies Beryl Capital entities and David A. Witkin as reporting persons with shared voting and dispositive power over the same 4,087,091 shares. The Partnership's separate 3,095,833-share holding (6.8%) is also disclosed. The certification language explicitly denies an intent to change or influence issuer control, which is consistent with a passive disclosure rather than an active governance engagement.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 45,438,420 shares of Common Stock outstanding on August 4, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 45,438,420 shares of Common Stock outstanding on August 4, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 45,438,420 shares of Common Stock outstanding on August 4, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 45,438,420 shares of Common Stock outstanding on August 4, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.


SCHEDULE 13G



Beryl Capital Management LLC
Signature:/s/ Andrew Nelson
Name/Title:Chief Operating Officer
Date:08/12/2025
Beryl Capital Management LP
Signature:/s/ Andrew Nelson
Name/Title:Chief Operating Officer of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP
Date:08/12/2025
Beryl Capital Partners II LP
Signature:/s/ Andrew Nelson
Name/Title:COO of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP, General Partner of Beryl Capital Partners II LP
Date:08/12/2025
David A. Witkin
Signature:/s/ David A. Witkin
Name/Title:Reporting person
Date:08/12/2025

Comments accompanying signature: EX. 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

FAQ

How many Y-mAbs (YMAB) shares does Beryl report owning?

The filing reports 4,087,091 shares beneficially owned by Beryl and related reporting persons.

What percentage of YMAB does the 4,087,091 shares represent?

The reported shares represent 9.0% of the outstanding common stock, based on 45,438,420 shares outstanding.

Does Beryl claim sole voting or dispositive power over these YMAB shares?

No. The filing reports 0 sole voting power and 4,087,091 shared voting power, and similarly for dispositive power.

Does the filing indicate Beryl intends to change or influence control of YMAB?

The certification in the filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

What is the Partnership's separately reported ownership in YMAB?

Beryl Capital Partners II LP is reported with 3,095,833 shares, equal to 6.8% of the class.
Y-Mabs Therapeutics

NASDAQ:YMAB

YMAB Rankings

YMAB Latest News

YMAB Latest SEC Filings

YMAB Stock Data

391.22M
39.89M
11.97%
82.81%
4.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON